Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK-guided pazopanib dose individualization study
NL-OMON22313Not yet recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of pazopanib in renal cell carcinoma (RCC) and Nonhematologic neoplasms, sponsored by Leiden University Medical Center. Primary endpoint: Interindividual variability in pazopanib exposure. Planned start Apr 2012; status: not yet recruiting.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON22313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22313.